James O. Armitage, M.D. Oncology–Hematology, University of Nebraska Medical Center, Omaha. Address reprint requests to Dr. Armitage at the Division of.

Slides:



Advertisements
Similar presentations
HODGKIN LYMPHOMA IN CHILDREN
Advertisements

Advances and Emerging Therapy for Lung Cancer
Breast Cancer in Pregnancy
Clinical Management of Lymphoma 新光醫院 血液腫瘤科 溫 武 慶.
Oncology and Palliative Care: Promoting the Comfort and Cure Model Parag Bharadwaj, MD FAAHPM.
‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.
Supervisor: Vs 楊慕華醫師 Presenter: CR 周益聖醫師 N Engl J Med 2012;367:
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Focusing on Hodgkin Disease
Basics of Pediatric Oncology Margret E. Merino, MD Pediatric Hematology/Oncology WRAMC.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
50 year old man with history of Hodgkin Lymphoma as a child, treated with mediastinal radiation, now presenting with severe heart failure.
Treatment Planning Hodgkin Lymphoma.
Se cond Cancers and Residual Disease in Patients Treated for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma by Helicobacter pylori Eradication and.
Wildiers H, et al. Lancet Oncol. 2007;8:1101. Breast Cancer in Elderly (>65 Years) Recommendations of the International Society of Geriatric Oncology Surgical.
Exercise Management Cancer. Pathophysiology Cancer is not a single disease; it is a collection of hundreds of diseases that share the common feature of.
Cardiovascular Morbidity Following Modern Treatment for Hodgkin Lymphoma: Age- and Sex- Specific Estimates of Risk in the Doxorubicin Era. D. Hodgson 1,
Hodgkin’s Lymphoma By: Tonya Weir and Paige Mathias Date: October 13, 2010.
FDG-PET Adapted Sequential Therapy with Brentuximab Vedotin and Augmented ICE Followed by Autologous Stem Cell Transplant for Relapsed and Refractory Hodgkin.
 Management varies with type of lymphoma and pt factors (co-morbidities, age, performance status, pt preferences)  Goal of tx can be curative, to prolong.
Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma Luigi Marcheselli, Raffaella Marcheselli, Alessia Bari, Eliana.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Background Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. It’s account for about one-third of all.
ENESTnd Update: Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and the Impact.
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
Involved Field Radiotherapy versus No Further Treatment in Patients with Clinical Stages IA/IIA Hodgkin Lymphoma and a “Negative” PET Scan After 3 Cycles.
 Aromatase inhibitors act by lowering estrogen in the circulation and in tumor cells in post- menopausal women.
K30 Case Presentation David Andorsky August 26, 2008.
Sequential Dose-Dense R-CHOP Followed by ICE Consolidation (MSKCC Protocol ) without Radiotherapy for Patients with Primary Mediastinal Large B Cell.
First Author: Radu Cristina Co-Authors: Stefan Anda Tripon Florin Crauciuc George Coordinators: Banescu Claudia, MD Demian Smaranda, MD The importance.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) combination therapy in front-line low-grade non-Hodgkin lymphoma (LG-NHL) is active.
Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.
Lymphoma Rob Jones. Aim and learning outcomes Aim ◦ To revise the key points of lymphoma Learning outcomes ◦ Revise the basics of haemopoiesis ◦ Understand.
Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously.
Hodgkin’s Lymphoma Hodgkin’s Lymphoma Disease in which malignant (cancer) cells form in the lymph system Type of cancer that develops in.
Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and at the End of Treatment with R-CHOP in High- Tumor Mass Follicular.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
Basis and Outcome of Axillary Dissection for Node Negative Axilla Gurpreet Singh Dept. Of Surgery P.G.I.M.E.R. These Power Point presentations are free.
Hematopoetic Cancers. Hematopoesis Leukemia New diagnoses each year in the US: 40, 800 Adults 3,500 Children 21,840 died of leukemia in 2010.
R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Friedberg.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.
Univariate Analyses Treatment Outcome And Patterns Of Relapse Following Adjuvant Carboplatin For Stage I Testicular Seminoma: Results From a 17 Year UK.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.
Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
BENEFIT OF CONSOLIDATIVE RADIATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY JACK PHAN, ALI MAZLOOM, L. JEFFREY.
Non-Hodgkin’s Lymphoma
Rob Corbett NCCN Christchurch
Savage KJ et al. Proc ASH 2015;Abstract 579.
1 Stone RM et al. Proc ASH 2015;Abstract 6.
NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma
JOURNAL OF CLINICAL ONCOLOGY 25:
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Director Department of Pediatric Hematology & Oncology Delhi, INDIA.
Response to chemotherapy
Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after initial chemotherapy is not always required.
Jonathan W. Friedberg M.D., M.M.Sc.
Ansell SM et al. Proc ASH 2012;Abstract 798.
What is the optimal management of an asymptomatic 62 year old with low tumor burden, stage IV, grade 1-2 FL? Answer: R-chemotherapy Peter Martin,
Gordon LI et al. Proc ASH 2010;Abstract 415.
Role for XRT in treatment of early stage Follicular lymphoma?
Lymphomas.
Presentation transcript:

James O. Armitage, M.D. Oncology–Hematology, University of Nebraska Medical Center, Omaha. Address reprint requests to Dr. Armitage at the Division of Oncology–Hematology, University of Nebraska Medical Center N Engl J Med 2010;363: R2 이정훈 / pf. 어완규 Early-Stage Hodgkin’s Lymphoma REVIEW

Introduction  “Hodgkin’s lymphoma” – incurable!! : radiotherapy - treatment technique in the early 20th century - led to long-term survival free of recurrent lymphoma in pt. with early-stage disease : staging - Ann Arbor Conference in staging laparotomy in pts with early stage (i.e., stage I or II)  imaging techniques and effective systemic therapies

Introduction  The rate of response to systemically administered anticancer agents in patients with Hodgkin’s lymphoma could be high. (Studies of the use of mechlorethamine in the 1940s)  Investigators at the National Cancer Institute combined four of drugs for use in the initial treatment of patients with disseminated Hodgkin’s lymphoma.  cure was possible with chemotherapy alone.  Radiotherapy  adjuvant chemotherapy in patients with high-risk, early-stage disease : reduction in the risk of relapse  Initial chemotherapy  adjuvant radiotherapy : smaller treatment fields

Introduction  Early-stage Hodgkin’s lymphoma - radiotherapy was not available to them. - chemotherapy alone yield a high rate of complete and durable remission Chemotherapy of childhood Hodgkin’s disease in Uganda. Lancet 1972;2: Childhood Hodgkin’s disease in Uganda: a ten year experience. Cancer 1978;42:  Increasing recognition of the long-term, toxic effects of treatment and the very high survival rates among patients with early-stage Hodgkin’s lymphoma who received the most recent therapy regimens.  reduce or eliminate the radiotherapy used in these regimens and to minimize the number of chemotherapy cycles : the efficacy of reduced cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. Engert et al. N Engl J Med 2010;363:32-44.

Introduction  Patients with early-stage Hodgkin’s lymphoma are not a homogeneous group  Treatment toxicities are changing as chemotherapy regimens and radiotherapy techniques change.  The most serious toxic effects of treatment tend to occur late  complicate the process of determining what treatment to recommend for a patient with early-stage Hodgkin’s lymphoma

 The variation in prognosis is wide among patients who have stage I or stage II disease (Ann Arbor Conference) - stage I : involvement of one LN–bearing site, with or without extension to an adjacent extranodal site - stage II : involvement of two or more nodal sites on one side of the diaphragm, with or without extension to an adjacent extranodal site  Many factors can worsen the prognosis for these patients, including the presence of systemic symptoms - fevers, drenching night sweats, or significant weight loss - ESR, the number of nodal sites involved, older age and a large mediastinal mass  Risk factors : Not everyone uses the same definitions!! Variations in Risk

 The primary goal of therapy is cure.  The 5-year survival rate for patients with early-stage Hodgkin’s lymphoma : 90% or higher  Particularly among patients with a good prognosis in studies with a very long period of follow-up, the number who die from treatment- related complications exceeds the number who die from lymphoma Treatment-Related Complications

Figure 1. Approximate Cumulative Risk of Recurrent Hodgkin’s Lymphoma, Second Malignant Conditions, and Cardiovascular Events among Patients Receiving Both Radiotherapy and Chemotherapy for Early- Stage Hodgkin’s Lymphoma.

 The frequency of late complications is dependent on the particular treatment used.  Affect quality of life but are unlikely to be lethal ( hypothyroidism, dry mouth, and dental caries )  Second malignant : average rate of approximately 1% per year for at least 30 years after treatment : the risk is particularly high among women younger than 30 years of age who receive thoracic radiotherapy : breast cancer develops in 30 to 40% of these patients in the 25 years after treatment ** reducing the radiation dose and field  decrease the rate at which second malignant conditions occur Treatment-Related Complications Radiotherapy

 Radiation-related cardiac disease : coronary artery disease, myocardial injury, valvular disease, or pericardial fibrosis - The risk of death from myocardial infarction is increased after thoracic radiotherapy, and that increased risk persists for more than 25 years. - Diastolic dysfunction after radiotherapy seems to be a marker for an increased risk of cardiac events Treatment-Related Complications Radiotherapy

 The risk of late complications after chemotherapy appears to be dependent on the type of drugs prescribed. - Mechlorethamine : myelodysplasia, acute myeloid leukemia, and lung cancer ( vs Chlorambucil : the risk of lung cancer was not elevated ) - alkylating agents or etoposide : myelodysplasia and acute myeloid leukemia - Doxorubicin (commonly used ABVD regimen) : congestive heart failure - Bleomycin (commonly used ABVD regimen) : pulmonary fibrosis Treatment-Related Complications chemotherapy

Treatment Strategies

 Pregnancy : the more frequent malignant conditions discovered during pregnancy - the need to avoid computed tomography and positron-emission tomography (PET), but abdominal ultrasonography can be used to detect subdiaphragmatic disease - with asymptomatic, early stage Hodgkin’s lymphoma : treatment can sometimes be delayed until after delivery - radiotherapy should be avoided during pregnancy - if treatment is required and the patient does not want a therapeutic abortion, the successful completion of pregnancy without fetal malformation is possible with ABVD or similar regimens Special Considerations

 Older Age : Patients with Hodgkin’s lymphoma who are 45 to 50 years of age or older have a poorer prognosis than younger patients - poor treatment outcome in some of these patients : susceptibility to the toxic effects of intensive therapy - Acute toxic effects are more likely to develop in elderly patients, and they have a higher relapse rate and a lower overall survival rate. - Elderly patients seem to benefit proportionally more than younger patients from the inclusion of doxorubicin in the treatment regimen Special Considerations

 HIV Infection : mixed-cellularity or lymphocyte-depletion histologic subtype : widespread disease, involvement of extranodal sites, and systemic symptoms - highly active antiretroviral therapy has dramatically improved the survival rate among patients with HIV infection who also have Hodgkin’s lymphoma. - HIV-infected patients with early-stage Hodgkin’s lymphoma should receive the same treatment as patients with early-stage disease who are not infected with HIV. Special Considerations

 Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma : 95% of patients who receive a diagnosis of Hodgkin’s lymphoma - classic Hodgkin’s lymphoma, not nodular lymphocyte-predominant Hodgkin’s lymphoma : low-grade, monoclonal B-cell, malignant condition : Like other low-grade B-cell cancers, can undergo transformation to diffuse, large B-cell lymphoma. - Radiotherapy appears to be a particularly important component of treatment for early stage disease and can induce a durable remission Special Considerations

 A common theme is the attempt to use PET scanning to individualize therapy and minimize the amount of treatment required for cure.  It appears that positive PET findings at the end of treatment is a significant adverse risk factor.  asymptomatic, nonbulky, early-stage Hodgkin’s lymphoma (with ESR< 50 mm/hr, < four nodal sites, < one site of extranodal extension )  ABVD alone  either ABVD or the Stanford V chemotherapy regimen (mechlorethamine, doxorubicin, etoposide,vincristine, vinblastine, bleomycin, and prednisone), + involved-field radiotherapy (IFRT)  bulky disease  ABVD (X6 > X4) or Stanford V combination chemotherapy + all receive involved-field radiotherapy (IFRT) National Comprehensive Cancer Network. NCCN guidelines & clinical resources. Accessed July 16, 2010 Treatment Selection

 In one series of 73 patients, - 13 had positive PET scans at the completion of ABVD as the first part of a combined radiotherapy–chemotherapy  2-year, failure-free survival rate : Positive scans : 69% : Negative scans : 95%  46 patients who underwent interim PET scanning (after completing two or three cycles of chemotherapy) - 20 had positive interim scans, 13 had negative scans at the completion of chemotherapy  2-year, failure-free survival rate : Positive scans : 92% : Negative scans : 96% Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009;20: Treatment Selection

 In a series of patients treated with ABVD chemotherapy alone - with a interim PET scan (after two or three cycles of a planned six cycles of treatment ) - progression-free survival rate of : Positive scans : 71% : Negative scans : 90%  If the patients with a positive interim PET scan had a negative PET scan after completing six cycles of treatment with ABVD  the adverse effect of the positive interim PET scan disappeared  positive interim PET scan did not necessarily predict a poor treatment outcome Early interim FDG-PET scan predicts outcome in non-bulky limited stage Hodgkin lymphoma, but may not guide use of consolidative radiotherapy. Blood 2008;112:518. Treatment Selection

 The treatment of patients with early-stage Hodgkin’s lymphoma is one of the success stories of modern oncology  More than 90% of such patients will survive for at least 5 years after diagnosis.  Clinical trials are now focusing on minimizing the intensity of treatment to avoid late, potentially fatal toxic effects.  chemotherapy regimen alone VS fewer cycles of chemotherapy + involved field radiotherapy  It will be important to watch for a point at which treatment becomes inadequate and the number of deaths from Hodgkin’s lymphoma will begin to increase Conclusions